COVID-19 Impact on Global Myasthenia Gravis Therapies Market Size, Status and Forecast 2020-2026

Published On: Jun 2020

Format: PDF

Publisher: QY Research

Pages: 97

Report ID: 471787

Myasthenia gravis is a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles, which are responsible for breathing and moving parts of the body, including the arms and legs.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Myasthenia Gravis Therapies market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Myasthenia Gravis Therapies industry.
Based on our recent survey, we have several different scenarios about the Myasthenia Gravis Therapies YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Myasthenia Gravis Therapies will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Myasthenia Gravis Therapies market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Myasthenia Gravis Therapies market in terms of revenue.
Players, stakeholders, and other participants in the global Myasthenia Gravis Therapies market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global Myasthenia Gravis Therapies market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global Myasthenia Gravis Therapies market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Myasthenia Gravis Therapies market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Myasthenia Gravis Therapies market.
The following players are covered in this report:
Alexion Pharmaceuticals
Novartis
CSL Behring
Grifols
...
Myasthenia Gravis Therapies Breakdown Data by Type
Ocular Myasthenia Gravis
Congenital Myasthenia Gravis
Generalized Myasthenia Gravis
Transient Myasthenia Gravis
Others
Myasthenia Gravis Therapies Breakdown Data by Application
Hospitals and Clinics
Diagnostic Centers
Academic and Research Organizations

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Myasthenia Gravis Therapies Revenue
1.4 Market Analysis by Type
1.4.1 Global Myasthenia Gravis Therapies Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Ocular Myasthenia Gravis
1.4.3 Congenital Myasthenia Gravis
1.4.4 Generalized Myasthenia Gravis
1.4.5 Transient Myasthenia Gravis
1.4.6 Others
1.5 Market by Application
1.5.1 Global Myasthenia Gravis Therapies Market Share by Application: 2020 VS 2026
1.5.2 Hospitals and Clinics
1.5.3 Diagnostic Centers
1.5.4 Academic and Research Organizations
1.6 Coronavirus Disease 2019 (Covid-19): Myasthenia Gravis Therapies Industry Impact
1.6.1 How the Covid-19 is Affecting the Myasthenia Gravis Therapies Industry
1.6.1.1 Myasthenia Gravis Therapies Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Myasthenia Gravis Therapies Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Myasthenia Gravis Therapies Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered

2 Global Growth Trends by Regions
2.1 Myasthenia Gravis Therapies Market Perspective (2015-2026)
2.2 Myasthenia Gravis Therapies Growth Trends by Regions
2.2.1 Myasthenia Gravis Therapies Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Myasthenia Gravis Therapies Historic Market Share by Regions (2015-2020)
2.2.3 Myasthenia Gravis Therapies Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Myasthenia Gravis Therapies Market Growth Strategy
2.3.6 Primary Interviews with Key Myasthenia Gravis Therapies Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Myasthenia Gravis Therapies Players by Market Size
3.1.1 Global Top Myasthenia Gravis Therapies Players by Revenue (2015-2020)
3.1.2 Global Myasthenia Gravis Therapies Revenue Market Share by Players (2015-2020)
3.1.3 Global Myasthenia Gravis Therapies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Myasthenia Gravis Therapies Market Concentration Ratio
3.2.1 Global Myasthenia Gravis Therapies Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Myasthenia Gravis Therapies Revenue in 2019
3.3 Myasthenia Gravis Therapies Key Players Head office and Area Served
3.4 Key Players Myasthenia Gravis Therapies Product Solution and Service
3.5 Date of Enter into Myasthenia Gravis Therapies Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)
4.1 Global Myasthenia Gravis Therapies Historic Market Size by Type (2015-2020)
4.2 Global Myasthenia Gravis Therapies Forecasted Market Size by Type (2021-2026)

5 Myasthenia Gravis Therapies Breakdown Data by Application (2015-2026)
5.1 Global Myasthenia Gravis Therapies Market Size by Application (2015-2020)
5.2 Global Myasthenia Gravis Therapies Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Myasthenia Gravis Therapies Market Size (2015-2020)
6.2 Myasthenia Gravis Therapies Key Players in North America (2019-2020)
6.3 North America Myasthenia Gravis Therapies Market Size by Type (2015-2020)
6.4 North America Myasthenia Gravis Therapies Market Size by Application (2015-2020)

7 Europe
7.1 Europe Myasthenia Gravis Therapies Market Size (2015-2020)
7.2 Myasthenia Gravis Therapies Key Players in Europe (2019-2020)
7.3 Europe Myasthenia Gravis Therapies Market Size by Type (2015-2020)
7.4 Europe Myasthenia Gravis Therapies Market Size by Application (2015-2020)

8 China
8.1 China Myasthenia Gravis Therapies Market Size (2015-2020)
8.2 Myasthenia Gravis Therapies Key Players in China (2019-2020)
8.3 China Myasthenia Gravis Therapies Market Size by Type (2015-2020)
8.4 China Myasthenia Gravis Therapies Market Size by Application (2015-2020)

9 Japan
9.1 Japan Myasthenia Gravis Therapies Market Size (2015-2020)
9.2 Myasthenia Gravis Therapies Key Players in Japan (2019-2020)
9.3 Japan Myasthenia Gravis Therapies Market Size by Type (2015-2020)
9.4 Japan Myasthenia Gravis Therapies Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Myasthenia Gravis Therapies Market Size (2015-2020)
10.2 Myasthenia Gravis Therapies Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Myasthenia Gravis Therapies Market Size by Type (2015-2020)
10.4 Southeast Asia Myasthenia Gravis Therapies Market Size by Application (2015-2020)

11 India
11.1 India Myasthenia Gravis Therapies Market Size (2015-2020)
11.2 Myasthenia Gravis Therapies Key Players in India (2019-2020)
11.3 India Myasthenia Gravis Therapies Market Size by Type (2015-2020)
11.4 India Myasthenia Gravis Therapies Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Myasthenia Gravis Therapies Market Size (2015-2020)
12.2 Myasthenia Gravis Therapies Key Players in Central & South America (2019-2020)
12.3 Central & South America Myasthenia Gravis Therapies Market Size by Type (2015-2020)
12.4 Central & South America Myasthenia Gravis Therapies Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Alexion Pharmaceuticals
13.1.1 Alexion Pharmaceuticals Company Details
13.1.2 Alexion Pharmaceuticals Business Overview and Its Total Revenue
13.1.3 Alexion Pharmaceuticals Myasthenia Gravis Therapies Introduction
13.1.4 Alexion Pharmaceuticals Revenue in Myasthenia Gravis Therapies Business (2015-2020))
13.1.5 Alexion Pharmaceuticals Recent Development
13.2 Novartis
13.2.1 Novartis Company Details
13.2.2 Novartis Business Overview and Its Total Revenue
13.2.3 Novartis Myasthenia Gravis Therapies Introduction
13.2.4 Novartis Revenue in Myasthenia Gravis Therapies Business (2015-2020)
13.2.5 Novartis Recent Development
13.3 CSL Behring
13.3.1 CSL Behring Company Details
13.3.2 CSL Behring Business Overview and Its Total Revenue
13.3.3 CSL Behring Myasthenia Gravis Therapies Introduction
13.3.4 CSL Behring Revenue in Myasthenia Gravis Therapies Business (2015-2020)
13.3.5 CSL Behring Recent Development
13.4 Grifols
13.4.1 Grifols Company Details
13.4.2 Grifols Business Overview and Its Total Revenue
13.4.3 Grifols Myasthenia Gravis Therapies Introduction
13.4.4 Grifols Revenue in Myasthenia Gravis Therapies Business (2015-2020)
13.4.5 Grifols Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details